Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.
Liby KT, Yore MM, Sporn MB. Liby KT, et al. Nat Rev Cancer. 2007 May;7(5):357-69. doi: 10.1038/nrc2129. Epub 2007 Apr 19. Nat Rev Cancer. 2007. PMID: 17446857 Review.
Rexinoids for prevention and treatment of cancer: opportunities and challenges.
Liby KT, Sporn MB. Liby KT, et al. Curr Top Med Chem. 2016 Jun 16. Online ahead of print. Curr Top Med Chem. 2016. PMID: 27320330
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT. Leal AS, et al. Among authors: liby kt. Cancer Lett. 2017 May 28;394:76-87. doi: 10.1016/j.canlet.2017.02.021. Epub 2017 Feb 27. Cancer Lett. 2017. PMID: 28254412
Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
Zhang D, Leal AS, Carapellucci S, Shahani PH, Bhogal JS, Ibrahim S, Raban S, Jurutka PW, Marshall PA, Sporn MB, Wagner CE, Liby KT. Zhang D, et al. Among authors: liby kt. Cancer Prev Res (Phila). 2019 Apr;12(4):211-224. doi: 10.1158/1940-6207.CAPR-18-0317. Epub 2019 Feb 13. Cancer Prev Res (Phila). 2019. PMID: 30760500 Free article.
PARP inhibitors for chemoprevention--reply.
To C, Sporn MB, Liby KT. To C, et al. Among authors: liby kt. Cancer Prev Res (Phila). 2014 Nov;7(11):1172. doi: 10.1158/1940-6207.CAPR-14-0264. Cancer Prev Res (Phila). 2014. PMID: 25368012 No abstract available.
Is lycopene an effective agent for preventing prostate cancer?
Sporn MB, Liby KT. Sporn MB, et al. Among authors: liby kt. Cancer Prev Res (Phila). 2013 May;6(5):384-6. doi: 10.1158/1940-6207.CAPR-13-0026. Epub 2013 Mar 12. Cancer Prev Res (Phila). 2013. PMID: 23483003
Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.
Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S. Belz JE, et al. Among authors: liby kt. Theranostics. 2017 Sep 26;7(17):4340-4349. doi: 10.7150/thno.18563. eCollection 2017. Theranostics. 2017. PMID: 29158830 Free PMC article.
CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages.
Ball MS, Shipman EP, Kim H, Liby KT, Pioli PA. Ball MS, et al. Among authors: liby kt. PLoS One. 2016 Feb 26;11(2):e0149600. doi: 10.1371/journal.pone.0149600. eCollection 2016. PLoS One. 2016. PMID: 26918785 Free PMC article.
A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.
So JY, Lin JJ, Wahler J, Liby KT, Sporn MB, Suh N. So JY, et al. Among authors: liby kt. PLoS One. 2014 Sep 17;9(9):e107616. doi: 10.1371/journal.pone.0107616. eCollection 2014. PLoS One. 2014. PMID: 25229616 Free PMC article.
Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer.
Liby KT. Liby KT. Dose Response. 2013 Aug 1;12(1):136-51. doi: 10.2203/dose-response.13-018.Liby. eCollection 2014 Jan. Dose Response. 2013. PMID: 24659938 Free PMC article.
68 results
Jump to page